Verified discoveries, trials, and approvals for this cancer type. Every story separates evidence strength, regulatory status, and guideline position.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Primary source cited
Last reviewed
In the randomized, open-label, phase 3 KEYNOTE-689 trial, adding pembrolizumab before and after surgery to standard treatment significantly extended event-free survival in patients with resectable, locally advanced, PD-L1-positive head and…
Primary source cited
Last reviewed
In the randomized, open-label, phase 3 KEYNOTE-689 trial, adding pembrolizumab before and after surgery to standard treatment significantly extended event-free survival in patients with resectable, locally advanced, PD-L1-positive head and…
Primary source cited
Last reviewed
Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
ClinicalTrials.gov — NCT06496178. NCT06496178.
Eligibility varies — review trial criteria.
Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer (New England Journal of Medicine). DOI 10.1056/NEJMoa2415434, PMID 40532178.
Applies to the exact indication stated.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.